OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: OraSure develops, manufactures, and markets oral fluid specimen collection devices, diagnostic products (including immunoassays), and cryosurgical systems for skin lesion removal. Key products include the OraQuick ADVANCE rapid HIV-1/2 test, OraSure/Intercept oral fluid collection devices, and the Histofreezer/Freeze Off cryosurgical systems. The company operates primarily in the United States and internationally, serving clinical laboratories, hospitals, public health organizations, and the over-the-counter (OTC) retail market.

Key Financial Metrics

Note: 2005 Net Income included a one-time income tax benefit of $18.2 million from the release of a valuation allowance on deferred tax assets. 2006 Net Income included a $3.4 million pre-tax charge for stock-based compensation expense under new accounting rules (SFAS 123R).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 2% to $68.2 million. This was driven by a 24% decline in cryosurgical systems revenue (primarily due to a 51% drop in domestic OTC sales to distributor Prestige) and an 18% decline in insurance risk assessment revenue. These declines were partially offset by a 12% increase in infectious disease testing revenue and a 17% increase in substance abuse testing revenue.
• Profitability: Operating income decreased 28% to $5.5 million, and Net Income decreased significantly to $5.3 million (compared to $27.4 million in 2005). The 2005 figure was anomalously high due to the tax benefit; excluding that, operating performance remained relatively stable despite higher R&D expenses.
• Expense Increases: Research and Development (R&D) expenses increased 64% to $8.6 million, driven by development of the OraQuick HCV test, OTC clinical trials for OraQuick ADVANCE, and stock-based compensation. General and Administrative expenses increased 7% due to stock-based compensation and legal fees.
• Debt Increase: Long-term debt increased to $10.0 million following a $10 million borrowing in June 2006 to finance the purchase of two corporate facilities in Bethlehem, Pennsylvania.

Guidance, Outlook, Risks, and Contingencies

• Strategic Outlook: Management expects R&D expenses to increase by approximately $8.0 million in 2007, primarily for clinical trials for the OraQuick ADVANCE OTC test and the OraQuick HCV test. Sales and marketing expenses are also expected to rise to support infectious disease market expansion.
• Key Risks & Contingencies:
  • Distributor Dispute (Prestige): Prestige Brands, the exclusive U.S./Canada OTC distributor for the Freeze Off product, acquired a competing product line (Wartner), which OraSure alleges breaches the distribution agreement. Arbitration has commenced, creating uncertainty for future OTC cryosurgical sales.
  • Supply Chain Dependency (BMX): bioMerieux (BMX) announced it will discontinue manufacturing the HIV-1 EIA screening test used with the OraSure device in 2007 and will not renew the agreement to supply antigen for the Western blot confirmatory test after December 31, 2007. OraSure is working to find alternative suppliers.
  • Regulatory Approvals: Future growth depends on obtaining FDA approval for the OraQuick ADVANCE test for OTC use and the OraQuick HCV test. Delays or failures in these approvals could significantly impact revenue.
  • Intellectual Property Litigation: OraSure is engaged in patent infringement litigation against Schering-Plough regarding cryosurgical technology. The outcome is uncertain and could impact future earnings.

Investor Verification Checklist

• BMX Replacement Strategy: Verify the status of finding a replacement for the BMX HIV-1 EIA screening test and Western blot antigen supply, as this is critical for the OraSure device revenue stream.
• Prestige Arbitration Outcome: Monitor the resolution of the dispute with Prestige Brands to assess the future viability of the domestic OTC cryosurgical market.
• OTC Regulatory Timeline: Track progress on clinical studies and FDA submission for the OraQuick ADVANCE OTC test, a key growth driver.
• Stock-Based Compensation Impact: Review the ongoing impact of SFAS 123R adoption on future earnings per share, as this will remain a significant non-cash expense.
• Abbott/GE Transition: Confirm the impact of Abbott Laboratories selling its diagnostics business (including OraQuick distribution rights) to General Electric on hospital market sales.